Through systematic analyses of the datasets from the cBioPortal for Cancer Genomics, we found that both ARID1A and ARID1B mutations were associated with an improved outcome for ICIs treatment in advanced NSCLC patients. The gene discussed is ARID1B; the disease is non-small cell lung carcinoma.